Recombinant Anti-Met (c-Met) (phospho Y1349) antibody [EP2367Y] (ab68141)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EP2367Y] to Met (c-Met) (phospho Y1349)
- Suitable for: Dot blot, WB, IP, IHC-P
- Reacts with: Human
Related conjugates and formulations
Overview
-
Product name
Anti-Met (c-Met) (phospho Y1349) antibody [EP2367Y]
See all Met (c-Met) primary antibodies -
Description
Rabbit monoclonal [EP2367Y] to Met (c-Met) (phospho Y1349) -
Host species
Rabbit -
Tested applications
Suitable for: Dot blot, WB, IP, IHC-Pmore details
Unsuitable for: Flow Cyt -
Species reactivity
Reacts with: Human -
Immunogen
Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.
-
Positive control
- WB: HeLa and A431 cell lysate IHC: Human breast carcinoma tissue IP: HeLa cells
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at -20°C. Stable for 12 months at -20°C. -
Storage buffer
pH: 7.2
Preservative: 0.05% Sodium azide
Constituents: 0.1% BSA, 40% Glycerol (glycerin, glycerine), 9.85% Tris glycine, 50% Tissue culture supernatant -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EP2367Y -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Compatible Secondaries
-
Isotype control
-
Positive Controls
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab68141 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
Dot blot |
Use at an assay dependent concentration.
|
|
WB |
1/1000 - 1/10000. Predicted molecular weight: 156 kDa.
|
|
IP |
1/20 - 1/150.
|
|
IHC-P | (4) |
1/50 - 1/100. Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
|
Notes |
---|
Dot blot
Use at an assay dependent concentration. |
WB
1/1000 - 1/10000. Predicted molecular weight: 156 kDa. |
IP
1/20 - 1/150. |
IHC-P
1/50 - 1/100. Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol. |
Target
-
Function
Receptor for hepatocyte growth factor and scatter factor. Has a tyrosine-protein kinase activity. Functions in cell proliferation, scattering, morphogenesis and survival. -
Involvement in disease
Note=Activation of MET after rearrangement with the TPR gene produces an oncogenic protein.
Note=Defects in MET may be associated with gastric cancer.
Defects in MET are a cause of hepatocellular carcinoma (HCC) [MIM:114550].
Defects in MET are a cause of renal cell carcinoma papillary (RCCP) [MIM:605074]. It is a subtype of renal cell carcinoma tending to show a tubulo-papillary architecture formed by numerous, irregular, finger-like projections of connective tissue. Renal cell carcinoma is a heterogeneous group of sporadic or hereditary carcinoma derived from cells of the proximal renal tubular epithelium. It is subclassified into common renal cell carcinoma (clear cell, non-papillary carcinoma), papillary renal cell carcinoma, chromophobe renal cell carcinoma, collecting duct carcinoma with medullary carcinoma of the kidney, and unclassified renal cell carcinoma.
Note=A common allele in the promoter region of the MET shows genetic association with susceptibility to autism in some families. Functional assays indicate a decrease in MET promoter activity and altered binding of specific transcription factor complexes.
Note=MET activating mutations may be involved in the development of a highly malignant, metastatic syndrome known as cancer of unknown primary origin (CUP) or primary occult malignancy. Systemic neoplastic spread is generally a late event in cancer progression. However, in some instances, distant dissemination arises at a very early stage, so that metastases reach clinical relevance before primary lesions. Sometimes, the primary lesions cannot be identified in spite of the progresses in the diagnosis of malignancies. -
Sequence similarities
Belongs to the protein kinase superfamily. Tyr protein kinase family.
Contains 3 IPT/TIG domains.
Contains 1 protein kinase domain.
Contains 1 Sema domain. -
Domain
The kinase domain is involved in SPSB1 binding. -
Post-translational
modificationsDephosphorylated by PTPRJ at Tyr-1349 and Tyr-1365. -
Cellular localization
Membrane. - Information by UniProt
-
Database links
- Entrez Gene: 4233 Human
- Omim: 164860 Human
- SwissProt: P08581 Human
- Unigene: 132966 Human
-
Alternative names
- AUTS9 antibody
- c met antibody
- D249 antibody
see all
Images
-
Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using ab68141 at a dilution of 1/50.
Perform heat mediated antigen retrieval with EDTA buffer pH 9 before commencing with IHC staining protocol.
-
All lanes : Anti-Met (c-Met) (phospho Y1349) antibody [EP2367Y] (ab68141) at 1/5000 dilution
Lane 1 : HeLa (Human cervix adenocarcinoma epithelial cell) serum starved for 24 h. Whole cell lysates
Lane 2 : HeLa (Human cervix adenocarcinoma epithelial cell) serum starved for 24 h and then treated with hepatocyte growth factor at 40ng/ml for 5 min. Whole cell lysates
Lane 3 : HeLa (Human cervix adenocarcinoma epithelial cell) serum starved for 24 h and then treated with hepatocyte growth factor at 40ng/ml for 5 min. Whole cell lysates. Then the membrane was incubated with phosphatase.
Lysates/proteins at 15 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution
Predicted band size: 156 kDa
Observed band size: 150 kDa why is the actual band size different from the predicted?
Exposure time: 30 secondsBlocking and diluting buffer and concentration: 5% NFDM/TBST.
The molecular weight of Met (c-Met) (phospho Y1349) and Met (c-Met) is different. Ab51067 could only recognize the pro-Met which is 190kDa, but ab68141 recognizes theβ-subunits which is 145kDa.
-
ab68141 at 1/150 dilution immunoprecipitating Met (c-Met) (phospho Y1349) in HeLa (human cervix adenocarcinoma) whole cell lysate observed at 150 kDa (lanes 1 and 2).
Lane 1 (input): HeLa cells starved for 24 hours, then treated with 40 ng/mL HGF for 5 minutes whole cell lysate, 10μg
Lane 2 (+): ab68141 + HeLa cells starved for 24 hours, then treated with 40 ng/mL HGF for 5 minutes whole cell lysate
Lane 3 (-): Rabbit monoclonal IgG (ab172730) instead of ab68141 in HeLa cells starved for 24 hours, then treated with 40 ng/mL HGF for 5 minutes whole cell lysateFor western blotting, VeriBlot for IP Detection Reagent (HRP) (ab131366), was used for detection at 1/10,000 dilution.
Blocking and Diluting buffer and concentration: 5% NFDM/TBST.
-
All lanes : Anti-Met (c-Met) (phospho Y1349) antibody [EP2367Y] (ab68141) at 1/10000 dilution
Lane 1 : A431 cell lysate, untreated
Lane 2 : A431 cell lysate, treated with AP
Lysates/proteins at 10 µg per lane.
Secondary
All lanes : HRP-labeled goat anti-rabbit at 1/2000 dilution
Predicted band size: 156 kDa
Observed band size: ~150 kDa why is the actual band size different from the predicted? -
Dot blot analysis of Met (c-Met) (phospho Y1349) phospho peptide (Lane 1), Met (c-Met) Non-phospho peptide (Lane 2), labelling Met (c-Met) (phospho Y1349) with ab68141 at a dilution of 1/1000. Peroxidase conjugated goat anti-rabbit IgG (H+L)) was used as the secondary antibody at a dilution of 1/2500.
Blocking and diluting buffer: 5% NFDM/TBST.
Exposure time: 3 minutes.
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
References (21)
ab68141 has been referenced in 21 publications.
- Huang WC et al. Novel function of THEMIS2 in the enhancement of cancer stemness and chemoresistance by releasing PTP1B from MET. Oncogene 41:997-1010 (2022). PubMed: 34974522
- Zhu C et al. Tumor-derived extracellular vesicles inhibit HGF/c-Met and EGF/EGFR pathways to accelerate the radiosensitivity of nasopharyngeal carcinoma cells via microRNA-142-5p delivery. Cell Death Discov 8:17 (2022). PubMed: 35013115
- Pereira PMR et al. Immuno-PET Detects Changes in Multi-RTK Tumor Cell Expression Levels in Response to Targeted Kinase Inhibition. J Nucl Med 62:366-371 (2021). PubMed: 32646879
- Chen X et al. Curcumin Inhibits HGF-Induced EMT by Regulating c-MET-Dependent PI3K/Akt/mTOR Signaling Pathways in Meningioma. Evid Based Complement Alternat Med 2021:5574555 (2021). PubMed: 34408780
- Zhao D et al. CXCR4 promotes gefitinib resistance of Huh7 cells by activating the c-Met signaling pathway. FEBS Open Bio 11:3115-3125 (2021). PubMed: 34555268